Morens, D. M. & Fauci, A. S. Emerging pandemic diseases: how we got to COVID-19. Cell 182, 1077–1092 (2020).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Toor, J. et al. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. eLife 10, e67635 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fan, V. Y., Jamison, D. T. & Summers, L. H. Pandemic risk: how large are the expected losses? Bull. World Health Organ. 96, 129–134 (2018).

Article  PubMed  Google Scholar 

Mascola, J. R. & Fauci, A. S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 20, 87–88 (2020).

Article  PubMed  CAS  Google Scholar 

Excler, J. L., Saville, M., Berkley, S. & Kim, J. H. Vaccine development for emerging infectious diseases. Nat. Med. 27, 591–600 (2021).

Article  PubMed  CAS  Google Scholar 

Gebre, M. S. et al. Novel approaches for vaccine development. Cell 184, 1589–1603 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Haynes, B. F. et al. Prospects for a safe COVID-19 vaccine. Sci. Transl. Med. 12, eabe0948 (2020).

Article  PubMed  CAS  Google Scholar 

Roth, G. A. et al. Designing spatial and temporal control of vaccine responses. Nat. Rev. Mater. 7, 174–195 (2022).

Article  PubMed  CAS  Google Scholar 

Cirelli, K. M. et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell 177, 1153–1171.e28 (2019).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Satti, I. et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect. Dis. 14, 939–946 (2014).

Article  PubMed  CAS  Google Scholar 

Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–5714.e11 (2021).

Article  PubMed  CAS  Google Scholar 

Wei, C. J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239–252 (2020).

Article  PubMed  CAS  Google Scholar 

Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med. 29, 247–257 (2023).

Article  PubMed  CAS  Google Scholar 

Graham, B. S., Gilman, M. S. A. & McLellan, J. S. Structure-based vaccine antigen design. Annu. Rev. Med. 70, 91–104 (2019).

Article  PubMed  CAS  Google Scholar 

Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O. & De Gregorio, E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469–481 (2016).

Article  PubMed  CAS  Google Scholar 

Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).

Article  PubMed  CAS  Google Scholar 

Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615–632 (2020).

Article  PubMed  CAS  Google Scholar 

Singh, A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat. Nanotechnol. 16, 16–24 (2021).

Article  PubMed  CAS  Google Scholar 

Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12, 978–990 (2013).

Article  PubMed  CAS  Google Scholar 

Verbeke, R., Hogan, M. J., Loré, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993–2005 (2022).

Article  PubMed  CAS  Google Scholar 

Diamond, M. S. & Kanneganti, T.-D. Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol. 23, 165–176 (2022).

Article  PubMed  CAS  Google Scholar 

Ziogas, A. & Netea, M. G. Trained immunity-related vaccines: innate immune memory and heterologous protection against infections. Trends Mol. Med. 28, 497–512 (2022).

Article  PubMed  CAS  Google Scholar 

Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A. & Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 18, 553–566 (2019).

Article  PubMed  CAS  Google Scholar 

Gasteiger, G. et al. Cellular innate immunity: an old game with new players. J. Innate Immun. 9, 111–125 (2017).

Article  PubMed  CAS  Google Scholar 

Worbs, T., Hammerschmidt, S. I. & Förster, R. Dendritic cell migration in health and disease. Nat. Rev. Immunol. 17, 30–48 (2017).

Article  PubMed  CAS  Google Scholar 

Swartz, M. A., Hubbell, J. A. & Reddy, S. T. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin. Immunol. 20, 147–156 (2008).

Article  PubMed  CAS  Google Scholar 

Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).

Article  PubMed  Google Scholar 

Brooks, J. T., Marks, P., Goldstein, R. H. & Walensky, R. P. Intradermal vaccination for monkeypox — benefits for individual and public health. N. Engl. J. Med. 387, 1151–1153 (2022).

Article  PubMed  Google Scholar 

Alu, A. et al. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine 76, 103841 (2022).

Article  PubMed  CAS  Google Scholar 

Bull, N. C. et al. Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1− CD4+ T cells. Mucosal Immunol. 12, 555–564 (2019).

Article  PubMed  CAS  Google Scholar 

Zhao, J. et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379–1391 (2016).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Carter, N. J. & Curran, M. P. Live attenuated influenza vaccine (FluMist®; FluenzTM). Drugs 71, 1591–1622 (2011).

Article  PubMed  CAS